



A Commercial-Stage Bioelectronic Medicine & Wellness Company

Nasdaq: ECOR

Corporate Presentation

May 2024

Forward Looking Statement

In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number of risks, uncertainties and assumptions, and you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements may be based upon current estimates and expectations about future events and financial and other trends. There is no guarantee that future results, performance or events reflected in the forward-looking statements will be achieved or occur. No person assumes responsibility for the accuracy and completeness of the forward-looking statements, and, except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those or our situation may change in the future.

Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date they are made and are only predictions that may be inaccurate. You should read the Risk Factors set forth in our reports filed from time to time with the Securities and Exchange Commission, which factors may cause our actual future results to be materially different from what we expect.



gammaCore

Sapphire™

1st FDA-cleared non-invasive
vagus nerve stimulator

- Fast acting, comfortable, easy to use hand-held option
- FDA Cleared for the prevention and treatment of primary headache in adults and adolescents
- No drug-drug interactions or drug-like side effects
- Can be used as a stand-alone therapy or alongside existing treatments
- Can use multiple times per day or month
- Cost dominance in the first-year when gammaCore therapy is used in conjunction with standard of care as supported by UK NICE guidance

Investment Summary

Platform Therapy

FDA cleared; proprietary, non-invasive vagus nerve stimulator (nVNS) positioned to unlock the broad potential of bioelectronic medicine

Consistent Topline Growth

Approximately \$16M revenue in 2023; 6-year revenue compounded annual growth rate (CAGR%) of 68%

Gross margin consistently above 80%

Diverse Market Opportunity

Primary Headache estimated to affect more than 39 million¹ adults in the U.S. Expanding into Wellness and Human Performance to take advantage of the \$5 trillion Digital Health and Wellness market²

Attractive Business Models

Variety of products, price points, and business models for different end users

Strong IP Portfolio


Patent coverage extends beyond 2037

1. American Migraine Foundation.

2. Digital Health & Wellness Market Size Trends Report, Forecast.

Benefits of nVNS (Non-invasive Vagus Nerve Stimulation)

- ✓ The vagus nerve affects multiple organs and systems
- ✓ Activates multiple mechanisms of action
- ✓ Evidence supports a variety of current and future treatment targets
- ✓ Personal use, pocket size, portable, easy to use, products
- ✓ Complementary to existing care



CNS: Reduces nociception, reduces cortical spreading depression, and other brain modulation effects; increases glymphatic flow

Cardiac: Reduces heart rate and blood pressure

Pulmonary: Increases bronchodilation

Hepatic: Regulation of gluconeogenesis

Gastrointestinal: Increases GI motility and secretions; satiation

Splenic: Detection and regulation of systemic inflammation

Active Channels With Revenue Growth Opportunities

VA Hospitals

Driving Rx headache sales in the Department of Defense and Community Care Network through the roughly 1,300 Department of Veterans Affairs and Military Treatment Facilities

US Commercial

Growth in Rx headache in the U.S commercial channel driven by cash pay business models, clinic-based system adoption, and DME suppliers

Non-Rx

Truvaga Plus launch for general wellness available via eCommerce store
TAC-STIM Human Performance for active-duty military

International

Continued sales in territories with favorable coverage decisions (NHS England, NHS Scotland, NHS Wales) while expanding territories with public reimbursement policies

Launched December 2022 with greater than \$1M of sales in 2023

Feel Calmer, Think Clearer, Sleep Better

Truvaga quickly works with your body to balance your nervous system, creating a deep, natural relaxation response to calm your racing mind. Helping you think more clearly, sleep more soundly and live life more fully.


LEARN MORE




Truvaga™ is a [general wellness product](#) and as such has not been evaluated by the US Food and Drug Administration. Truvaga products are not intended to diagnose, treat, cure, or prevent any disease or condition.

Cognitive Function and Stress Remain an Unmet Need for Consumer

Global stress market is estimated at \$20.6 billion with the U.S. stress market growing at a 5.3% CAGR(%)¹



Source: McKinsey Future of Wellness Survey, August 2023



Source: Truvaga Consumer Study

1. <https://www.grandviewresearch.com/industry-analysis/us-workplace-stress-management-market-report>. CAGR(%) is 2023 – 2030.

Introducing.... Truvaga Plus

Launched April 2024 with approximately 300 units sold in the first three weeks




Welcome to Truvaga!

We're thrilled you've chosen Truvaga Plus as part of your wellness journey.

Our Truvaga vagus nerve therapy is now better than ever with Truvaga Plus. It has new app-enablement and rechargeable features, along with unlimited* sessions.

Download the App to get started!




TAC-STIM

TAC-STIM has been developed with support from the 711th Human Performance Wing Performance Optimization Branch of the United States Air Force to provide:

- Accelerated Training
- Sustained Attention
- Reduced Fatigue
- Improved Mood

Additional information can be found at www.tac-stim.com.



TAC-STIM™ is a [general wellness product](#) and as such has not been evaluated by the US Food and Drug Administration. TAC-STIM products are not intended to diagnose, treat, cure, or prevent any disease or condition.

TAC-STIM in Active-Duty Military

Active-Duty Use Cases:

TRAINING

- Foreign Language Initial Acquisition Program
- School Houses
- Special Ops training
- Other specific training environments

MISSION SUPPORT

- Preparation
- Increase vigilance
- Decrease fatigue
- Improve performance

POST MISSION

- After action debrief
- Facilitate decompression
- Learning consolidation
- Physical and mental restoration

PUBLISHED FORCE AND MISSION RELEVANT RESULTS¹

TAC-STIM Enhances
ISR Synthetic Aperture Radar Training

TAC-STIM Improves Cognitive Skill
After Sleep Deprivation

TAC-STIM Boosts Mood and Performance
During ISR FMV Training

TAC-STIM Improves Difficult Language Recall
and Recognitions

1. Visit www.tac-stim.com for additional information

nVNS – A Platform Technology

Rx Products


Wellness Products

Human Performance

Existing Product Offerings



Future Product Offerings



Prescription gammaCore – Pipeline of Possible Future Indications

- Primary Headache¹
- Post-traumatic stress disorder^{2,3}
- Opioid Use Disorder²
- Traumatic Brain Injury²
- Parkinson's Disease²
- Acute Stroke²
- Gastroparesis²

**gammaCore is the
only FDA-cleared
non-invasive
VNS therapy in
primary headache**

¹ Cleared indications, ²Independent Investigator, initiated studies ongoing, ³Breakthrough Designation

gammaCore (nVNS) currently is FDA-cleared for prevention of migraine and cluster headache, and acute treatment of migraine and episodic cluster headache, as well as the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age

Broad Intellectual Property Portfolio

electroCore owns all intellectual property on which the technology relies

Expansive pioneering IP coverage of non-invasive, transdermal neuro-stimulation in the neck

We have patent coverage extending beyond 2037:

- High-frequency burst signals capable of passing comfortably through the skin
- Low-pass signal filtration that reduces signal harmonics that cause pain
- Growing digital health portfolio

>200

PATENTS AND PATENT APPLICATIONS

~140 issued U.S. patents


~35 U.S. patent applications

~35 International patents and applications

Summary Financials and Guidance

Net Sales
\$ in thousands

61% 5-year CAGR




Revenue and Cash

Q1 2024 revenue: \$5.4 million

Cash, cash equivalents and restricted cash of approximately \$8.1 million as of March 31, 2024

Summary Revenue by Quarter



*Unaudited Actuals

Capitalization Table

Fully diluted as of March 31, 2024
(in thousands)

| | | |
|-------------------------------------|--------------|---|
| Common Shares | 6,006 | |
| Pre-Funded Warrants | 613 | |
| Warrants | 924 | Average Exercise price = \$4.54 |
| Options | 501 | Average Exercise price = \$37.03 |
| Restricted and Deferred Stock Units | 425 | RSUs/DSUs which vest through January 2027 |
| Total | 8,469 | |

Experienced Management Team



Dan Goldberger
Chief Executive
Officer



Brian Posner
Chief Financial
Officer



Peter Staats
Chief Medical Officer



Joshua Lev
Chief Strategy
Officer



Potential Catalysts 2024/2025

- Accelerating Revenue in prescription gammaCore
- Truvaga Plus commercial launch
- TAC-STIM contract wins
- Future label extensions
- Data readouts in concussion, Parkinson's, and/or stroke

Investment Summary

Platform Therapy

FDA cleared; proprietary, non-invasive vagus nerve stimulator (nVNS) positioned to unlock the broad potential of bioelectronic medicine

Consistent Topline Growth

Approximately \$16M revenue in 2023; 6-year revenue compounded annual growth rate (CAGR%) of 68%

Gross margin consistently above 80%

Diverse Market Opportunity

Primary Headache estimated to affect more than 39 million¹ adults in the U.S. Expanding into Wellness and Human Performance to take advantage of the \$5 trillion Digital Health and Wellness market²

Attractive Business Models

Variety of products, price points, and business models for different end users

Strong IP Portfolio

Patent coverage extends beyond 2037

1. American Migraine Foundation.

2. Digital Health & Wellness Market Size Trends Report, Forecast.



A Commercial-Stage Bioelectronic Medicine & Wellness Company


Nasdaq: ECOR

Appendix

Leveraging nVNS in the \$5 trillion Digital Health and Wellness Market




CAGR% in the growing Health and Wellness Economy²



1. Digital Health & Wellness Market Size Trends Report, Forecast.
2. Source: Canaccord Genuity Industry Update: Health, Wellness and Lifestyle. Figure 4. January 4, 2024.

Commercial Strategy



Grow prescription nVNS business

- Our VA Hospital channel is accelerating and can be scaled
- Replicate the VA model with Joerns healthcare in a managed care system
- Grow our cash pay clinician dispense channel while we work towards broader reimbursement
- Add product to our prescription channels
 - Label extensions to PTSD, OUD, Parkinson's, etc.

Grow Truvaga Direct to Consumer wellness business

- KPIs include revenue, MER (media efficiency), return rate
- Launch Truvaga Plus in 2024

Grow pipeline of human performance in active-duty military and civilian crossover

Balance sheet gives us ability to execute

United States Government Sales



Lovell Government Services

- Lovell is a Service-Disabled Veteran Owned Small Business (SDVOSB) that acts as federal distribution partner across all government contract
- Lovell has access to the SDVOSB budget set-aside for VAs to meet their SDVOSB purchase requirements
- gammaCore products available to federal customers on the Medical Surgical Federal Supply Schedule (FSS), the DoD's Distribution and Pricing Agreement (DAPA), GSA Advantage, and Electronic Catalog (ECAT) procurement portals through Lovell

electroCore's Existing FSS Contract (36F79719D0063)


- gammaCore continues to be sold directly to FSS eligible entities and via open market sales to certain individual VA facilities

electroCore is currently selling to the VA Hospital channel under our own FSS contract, to individual VA hospitals through open market sales, and through Lovell Government Services


Mechanism of Action

nVNS: An Integrative Mechanism of Action

There are multiple known mechanism of vagus nerve stimulation:




Growth in VA/DoD Prescribing Facilities




~1,300^{1,2} VA, DoD, and Indian Health Service treatment facilities

Growth in Cumulative Revenue Generating Cash Pay Prescribers



Summary Financials and Guidance



Revenue and Cash

Q1 2024 revenue: \$5.4 million

Cash, cash equivalents and restricted cash of approximately \$8.1 million as of March 31, 2024

*Unaudited Actuals

Global Approvals

FDA-Cleared Indications for the US

- The preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients.
- The acute treatment of pain associated with migraine headache in adolescent (age 12 and older) and adult patients.
- Adjunctive use for the preventive treatment of cluster headache in adult patients.
- The acute treatment of pain associated with episodic cluster headache in adult patients.
- Treatment of hemicrania continua in adults.
- Treatment of paroxysmal hemicrania in adults.

US FDA guidance document titled: “General Wellness: Policy for Low-Risk Devices, Guidance for Industry and Food and Drug Administration Staff”

Meets the following two factors, and,

- Is intended for only general wellness use
- Presents a low risk to the safety of users and other persons

It's intended uses involve claims about sustaining or offering general improvement to functions associated with a general state of health that do not make any reference to diseases or conditions. Examples of these include, but are not limited to “claims” related to:

- relaxation or stress management (including claims to promote relaxation or manage stress)
- mental acuity (including claims to improve mental acuity, instruction following, concentration, problem-solving, multitasking, resource management, decision-making, logic, pattern recognition, or eye-hand coordination, as well as enhancing learning capacity)

CE Marks for the EU/EFTA/EEA and UK

- Acute and/or prophylactic treatment of primary headache (migraine, cluster headache, and hemicrania continua) and medication overuse headache in adults.
- Treatment or prevention of symptoms of reactive airway disease, including asthma, bronchoconstriction, exercise-induced bronchospasm, and COPD.
- Adjunctive therapy for adults to reduce the symptoms of certain anxiety and depression conditions (including panic disorder, posttraumatic stress disorder, obsessive-compulsive disorder, and major depressive disorder).
- Adjunctive therapy in the prevention of partial onset and generalized seizures associated with epilepsy in adults.
- Adjunctive therapy for adults to reduce the symptoms of gastric motility disorders and irritable bowel syndrome (including nausea, vomiting, bloating/distention, early satiety, and abdominal pain).

Health Canada License for Canada

- Acute and/or prophylactic treatment of migraine in adolescents and adults and cluster headache in adults.

ARTG Certificate for Australia

- Acute and/or prophylactic treatment of migraine, cluster headache, and hemicrania continua in adults.

Rx gammaCore Important Safety Information

gammaCore Sapphire™ (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for:

- The preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients.
- The acute treatment of pain associated with migraine headache in adolescent (age 12 and older) and adult patients.
- Adjunctive use for the preventive treatment of cluster headache in adult patients.
- The acute treatment of pain associated with episodic cluster headache in adult patients.
- Treatment of hemicrania continua in adults.
- Treatment of paroxysmal hemicrania in adults.

The effectiveness of gammaCore (nVNS) has not been established in the acute treatment of chronic cluster headache.

The long-term effects of the chronic use of the device have not been established.

gammaCore contraindications include but are not limited to:

- Patients that have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
- Patients that have a metallic device such as a stent, bone plate, or bone screw implanted in or near the neck
- Patients that are using another device at the same time (e.g., TENS unit, muscle stimulator) or any portable electronic device (e.g., cell phone).

Safety and efficacy of gammaCore have not been evaluated in the following patients, and therefore gammaCore is NOT indicated for:

- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
- Patients who have undergone surgery for resection of the vagus nerve in the neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia

The long-term safety and effectiveness of the gammaCore device has not been demonstrated in adolescents 12-17 years of age. Due to hormonal and cognitive development changes in adolescents, this population should be closely monitored while using the device. The use of the device in this population is based on extrapolated data from a clinical study in adults.

- You must read the gammaCore Instructions for Use before using gammaCore
- Only use gammaCore as described in these Instructions for Use or as otherwise directed by your Healthcare Provider
- Only use an electroCore-approved electrode gel with gammaCore.

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders, such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product: www.gammacore.com

Please also see the instructions for Use for gammaCore CV for all the important warnings and precautions specific to gammaCore CV and its use pursuant to the Emergency Use Authorization (EUA): <https://www.fda.gov/media/139970/download>

Truvaga and TAC-STIM Important Safety Information

Warnings

Do not use Truvaga or TAC-STIM if:

- You have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic product.
- You are in an explosive atmosphere or in the presence of flammable gas mixtures.
- You have an open wound at the application site.

Precautions

- Truvaga and TAC-STIM should be used only as described in the User Manual.
- Do not apply Truvaga or TAC-STIM across or through the head, directly on the eyes, covering the mouth, on the chest, on the upper back, or over the heart.
- Do not use Truvaga or TAC-STIM if there are signs of damage or defects.
- Do not use if an error code is displayed on the screen when the product is turned on.
- Do not submerge Truvaga or TAC-STIM in water; it is not water resistant.

NOTE: There is no data on the use of Truvaga or TAC-STIM if you are pregnant or breastfeeding.

Users with sensitive skin may experience application site discomfort, irritation and/or redness. If you experience light-headedness, dizziness, chest pain, excessive skin irritation, local pain, face/head/neck area (including toothache), excessive muscle twitching, tingling, contractions, or other adverse reactions, DISCONTINUE USE. These reactions typically resolve after the session is complete; however, if it persists after the session, consult your physician. Please refer to the Truvaga User Manual and Quick Start Guide for all of the important warnings and precautions before using the product.

Truvaga™ and TAC-STIM™ are general wellness products and as such have not been evaluated by the US Food and Drug Administration. Truvaga and TAC-STIM products are not intended to diagnose, treat, cure, or prevent any disease or condition.